Cargando…

Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial

BACKGROUND: Acute heart failure (AHF) is a common presentation in the Emergency Department (ED), and most patients are admitted to the hospital. Identification of patients with AHF who have a low risk of adverse events and are suitable for discharge from the ED is difficult, and an objective tool wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, Benton R, Collins, Sean P, Fermann, Gregory J, Levy, Phillip D, Shen, Changyu, Ayaz, Syed Imran, Cole, Mette L, Miller, Karen F, Soliman, Adam A, Pang, Peter S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441668/
https://www.ncbi.nlm.nih.gov/pubmed/28572743
http://dx.doi.org/10.2147/POR.S130807
_version_ 1783238303155224576
author Hunter, Benton R
Collins, Sean P
Fermann, Gregory J
Levy, Phillip D
Shen, Changyu
Ayaz, Syed Imran
Cole, Mette L
Miller, Karen F
Soliman, Adam A
Pang, Peter S
author_facet Hunter, Benton R
Collins, Sean P
Fermann, Gregory J
Levy, Phillip D
Shen, Changyu
Ayaz, Syed Imran
Cole, Mette L
Miller, Karen F
Soliman, Adam A
Pang, Peter S
author_sort Hunter, Benton R
collection PubMed
description BACKGROUND: Acute heart failure (AHF) is a common presentation in the Emergency Department (ED), and most patients are admitted to the hospital. Identification of patients with AHF who have a low risk of adverse events and are suitable for discharge from the ED is difficult, and an objective tool would be useful. METHODS: The highly sensitive Troponin T Rules Out Acute Cardiac Insufficiency Trial (TACIT) will enroll ED patients being treated for AHF. Patients will undergo standard ED evaluation and treatment. High-sensitivity troponin T (hsTnT) will be drawn at the time of enrollment and 3 hours after the initial draw. The initial hsTnT draw will be no more than 3 hours after initiation of therapy for AHF (vasodilator, loop diuretic, noninvasive ventilation). Treating clinicians will be blinded to hsTnT results. We will assess whether hsTnT, as a single measurement or in series, can accurately predict patients at low risk of short-term adverse events. CONCLUSION: TACIT will explore the value of hsTnT measurements in isolation, or in combination with other markers of disease severity, for the identification of ED patients with AHF who are at low risk of short-term adverse events.
format Online
Article
Text
id pubmed-5441668
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54416682017-06-01 Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial Hunter, Benton R Collins, Sean P Fermann, Gregory J Levy, Phillip D Shen, Changyu Ayaz, Syed Imran Cole, Mette L Miller, Karen F Soliman, Adam A Pang, Peter S Pragmat Obs Res Study Protocol BACKGROUND: Acute heart failure (AHF) is a common presentation in the Emergency Department (ED), and most patients are admitted to the hospital. Identification of patients with AHF who have a low risk of adverse events and are suitable for discharge from the ED is difficult, and an objective tool would be useful. METHODS: The highly sensitive Troponin T Rules Out Acute Cardiac Insufficiency Trial (TACIT) will enroll ED patients being treated for AHF. Patients will undergo standard ED evaluation and treatment. High-sensitivity troponin T (hsTnT) will be drawn at the time of enrollment and 3 hours after the initial draw. The initial hsTnT draw will be no more than 3 hours after initiation of therapy for AHF (vasodilator, loop diuretic, noninvasive ventilation). Treating clinicians will be blinded to hsTnT results. We will assess whether hsTnT, as a single measurement or in series, can accurately predict patients at low risk of short-term adverse events. CONCLUSION: TACIT will explore the value of hsTnT measurements in isolation, or in combination with other markers of disease severity, for the identification of ED patients with AHF who are at low risk of short-term adverse events. Dove Medical Press 2017-05-18 /pmc/articles/PMC5441668/ /pubmed/28572743 http://dx.doi.org/10.2147/POR.S130807 Text en © 2017 Hunter et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Study Protocol
Hunter, Benton R
Collins, Sean P
Fermann, Gregory J
Levy, Phillip D
Shen, Changyu
Ayaz, Syed Imran
Cole, Mette L
Miller, Karen F
Soliman, Adam A
Pang, Peter S
Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial
title Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial
title_full Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial
title_fullStr Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial
title_full_unstemmed Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial
title_short Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial
title_sort design and rationale of the high-sensitivity troponin t rules out acute cardiac insufficiency trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441668/
https://www.ncbi.nlm.nih.gov/pubmed/28572743
http://dx.doi.org/10.2147/POR.S130807
work_keys_str_mv AT hunterbentonr designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial
AT collinsseanp designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial
AT fermanngregoryj designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial
AT levyphillipd designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial
AT shenchangyu designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial
AT ayazsyedimran designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial
AT colemettel designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial
AT millerkarenf designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial
AT solimanadama designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial
AT pangpeters designandrationaleofthehighsensitivitytroponintrulesoutacutecardiacinsufficiencytrial